A role for MET signalling in TIC biology has been documented in several cancers including glioblastoma, prostate, pancreatic and breast cancers59–66, where MET acts as a functional marker of TICs, facilitating their survival under stress such as hypoxia, as well as conferring therapeutic resistance and metastatic potential59–62,66–68. This evidence concerns the gene MET and cancer.